GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
IZIGROUP CEO eyes international opportunities after ‘exceeding all targets’
IZI Finance plc has just announced its audited results, and the group surpassed €1 billion in both turnover and player ...
Antonia Zammit appointed Non-Executive Director of Simonds Farsons Cisk
Antonia Zammit replaces outgoing Director Marina Hogg.
Indiscriminate PEP rules undermine ability to attract talent for public appointments – Norman Aquilina
'Malta has a Politically Exposed Person (PEP) paradox that has become a competence trap.'
Ready to shape the next chapter of financial services regulation?
Malta's financial watchdog is seeking five Deputy Chief Executive Officers to join its Executive Leadership team.
